AstraZeneca PLC (AZN)vsMaravai Lifesciences Holdings Inc (MRVI)
AZN
AstraZeneca PLC
$173.30
-1.09%
HEALTHCARE · Cap: $261.94B
MRVI
Maravai Lifesciences Holdings Inc
$6.59
-3.94%
HEALTHCARE · Cap: $2.47B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 29421% more annual revenue ($60.44B vs $204.73M). AZN leads profitability with a 17.2% profit margin vs -51.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
MRVI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$173.30
$20.66 discount
Intrinsic value data unavailable for MRVI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Revenue surging 40.5% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Operating margin of 1.1%
Elevated debt levels
Weak financial health signals
ROE of -49.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : MRVI
The strongest argument for MRVI centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : MRVI
The primary concerns for MRVI are Operating Margin, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while MRVI is a hypergrowth play — different risk/reward profiles.
MRVI carries more volatility with a beta of 0.65 — expect wider price swings.
MRVI is growing revenue faster at 40.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Maravai Lifesciences Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?